Michael Hall wins Charles Rodolphe Brupbacher Prize for Cancer Research 2019

    -     Deutsch
Michael Hall, laureate of the Charles Rodolphe Brupbacher Prize for Cancer Resea

Michael Hall, laureate of the Charles Rodolphe Brupbacher Prize for Cancer Research 2019. (Image: Matthew Lee, Biozentrum)

Michael Hall of the Biozentrum of the University of Basel is awarded the Charles Rodolphe Brupbacher Prize for Cancer Research 2019. The prize recognizes his discovery of the TOR enzyme which controls cell growth via a complex signalling network. His work has made a key contribution to the development of new cancer drugs. The award ceremony will take place on 31 January 2019 in Zurich.

The prize worth 100,000 Swiss francs, established by Frédérique Brupbacher in memory of her husband Charles Rodolphe Brupbacher, will be awarded for the 14 th time in January 2019, and is one of the most renowned awards for scientists working in cancer research world-wide. In 2019 the award will be presented to Michael Hall, Professor of Biochemistry at the University of Basel’s Biozentrum, for his fundamental discovery of the basic mechanism of cell growth control and how this contributes to cancer development.

Central control of cell growth discovered

In the early 1990s, while working at the Biozentrum in Basel, Michael Hall discovered the protein TOR (Target of Rapamycin). Using yeast as a simple model organism, Hall found that the TOR kinase is a central controller of cell growth and metabolism. The TOR enzyme is also found in all higher organisms, from worms and plants to mammals, in which it is known as mTOR. TOR forms two different multi-protein complexes, which function via a complicated network of signalling pathways. If the TOR signalling pathways are normally activated, the cell turns on its growth machinery and suppresses catabolic processes. In some cancers, TOR is abnormally activated.

Basis for targeted cancer treatment

Rapamycin is secreted by a soil bacterium and was initially found to inhibit fungal growth. After this first discovery, TOR was also found to act as an immunosuppressant and as well to block tumor growth. Michael Hall was able to show that faulty regulation of the mTOR signalling pathways is implicated in diseases such as cancer, diabetes and cardiovascular disease. Today, rapamycin and its derivatives are used to prevent organ rejection in transplant patients and to treat cancer. mTOR inhibitors have been used successfully for many years in the treatment of different types of cancer including kidney, pancreas, breast, stomach and lung. Indeed, the life expectancy of some patients with advanced cancer has been shown to be significantly extended by mTOR inhibitors.

Charles Rodolphe Brupbacher Symposium 2019

Location: ETH Zurich, Main Building, AudiMax (HG F 30), Rämistrasse 101, Zurich

Public Lecture "Microbial infections as a cause of cancer" (lecture held in German)

Anne Müller, Institute of Molecular Cancer Research, University of Zurich

Tuesday, 29 January 2019, 7:00 p.m. to 8:00 p.m.

14 th Charles Rodolphe Brupbacher Symposium

"Breakthroughs in Cancer Research and Therapy"

Wednesday, 30 January to Friday, 1 February 2019

In English, admission free, seat number limited

Registration deadline: 27 January 2019

Award Ceremony Charles Rodolphe Brupbacher Prize for Cancer Research 2019

The prize is awarded to scientists who have made extraordinary contributions to basic oncological research. Prize money: CHF 100,000 each

Thursday, 31 January 2019, 5:15 p.m. to 6:30 p.m.

Young Investigator Awards

The award is bestowed upon up to five young investigators under the age of 35 who submit, as first author, one of the over one hundred and fifty poster abstracts for the academic symposium. Prize money: CHF 2,000 per poster abstract

Friday, 1 February 2019, 11:30 a.m. to 12:00 noon

About the Foundation

The mission of the Foundation is to foster cancer research in Switzerland and internationally. It was founded by Frédérique Brupbacher in memory of her late husband Charles Rodolphe Brupbacher who had died of cancer. Until her death in 2015, Frédérique Brupbacher presided over the Foundation with a great deal of commitment. During her final years, the Foundation that she had set up became her most important purpose in life. She therefore took a very active role in developing it and was able to personally attend the first eleven scientific C. R. Brupbacher Symposia und hand over the prizes.

Key elements of the Charles Rodolphe Brupbacher Foundation's activities biennially are:

- Bestowal of the Charles Rodolphe Brupbacher Prize for Cancer Research;

- Organisation of the scientific C. R. Brupbacher Symposium in Zurich;

- Bestowal of a maximum of five Charles Rodolphe Brupbacher Young Investigator Awards;

- Lecture on cancer research for the public in German.

The seat of the Foundation is in Vaduz, Principality of Liechtenstein. In scientific matters it works closely together with the University of Zurich, especially with the Medical Faculty. In terms of cancer research and cancer treatment the University of Zurich and the University Hospitals and Clinics of Zurich are among the best in the world. One of the objectives of the scientific C. R. Brupbacher Symposium is also to strengthen Zurich as a research location for oncology and to promote the international exchange of information among scientists in Zurich.